Nov 14 (Reuters) - Commonwealth Bank of Australia (CBA) :
- QTRLY UNAUDITED STATUTORY NPAT A$ 2.5 BILLION VERSUS A$2.7 BILLION REPORTED LAST YEAR
- AUSTRALIAN ECONOMY REMAINS RESILIENT, SUPPORTED BY LOW UNEMPLOYMENT AND STRONG POPULATION GROWTH
- QTRLY UNAUDITED CASH NPAT A$2.5 BILLION VERSUS A$2.5 BILLION REPORTED LAST YEAR
- WE HAVE DELIVERED SOLID FINANCIAL OUTCOMES IN QUARTER
- AS AT SEPT-END, CET1 (LEVEL 2) RATIO OF 11.8%
- HIGHER INTEREST RATES ARE RESULTING IN SLOWING GROWTH AND CONSUMER SPENDING, WITH PRESSURE ON SOME HOUSEHOLDS AND BUSINESSES IN AUSTRALIA
- WE ARE VERY CONSCIOUS THAT MANY AUSTRALIANS ARE FEELING UNDER PRESSURE IN CURRENT ENVIRONMENT
- REMAIN OPTIMISTIC ON MEDIUM-TERM OUTLOOK FOR AUSTRALIA
- QTRLY LOAN IMPAIRMENT EXPENSE WAS A$198 MILLION
- WE HAVE SEEN A MODEST INCREASE IN CONSUMER ARREARS OVER RECENT MONTHS
- BALANCE SHEET STRENGTH COMBINED WITH OUR STRONG ORGANIC CAPITAL GENERATION ALLOWS US TO SUPPORT OUR CUSTOMERS THROUGH CHALLENGING TIMES
- HAS COMPLETED THE PURCHASE OF MORE THAN A$700 MILLION OF SHARES ON-MARKET TO NEUTRALISE THE IMPACT OF THE 2H23 DIVIDEND REINVESTMENT PLAN
- KEY CREDIT QUALITY INDICATORS REMAINED SOUND IN QUARTER WITH CONSUMER ARREARS REMAINING AT HISTORICALLY LOW LEVELS
- STRONG BANKS BENEFIT ALL AUSTRALIANS, AND WE REMAIN WELL POSITIONED TO CONTINUE TO SUPPORT OUR CUSTOMERS
- WE REMAIN WELL POSITIONED TO INVEST IN OUR COMMUNITIES AND PROVIDE STRENGTH AND STABILITY FOR BROADER AUSTRALIAN ECONOMY
- HAVE MADE GOOD PROGRESS ON OUR FY24 FUNDING REQUIREMENTS WITH A$17 BILLION RAISED TO DATE, REPRESENTING ABOUT 50% OF FY24 FUNDING TASK
- Forums
- ASX - By Stock
- CBA
- News: CBA CBA Posts Qtrly Unaudited Statutory NPAT Of A$2.5 Billion
CBA
commonwealth bank of australia.
Add to My Watchlist
2.81%
!
$185.36

News: CBA CBA Posts Qtrly Unaudited Statutory NPAT Of A$2.5 Billion
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$185.36 |
Change
-5.350(2.81%) |
Mkt cap ! $310.1B |
Open | High | Low | Value | Volume |
$190.50 | $191.06 | $185.36 | $367.6M | 1.971M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 4521 | $185.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$185.88 | 70 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 4521 | 185.360 |
1 | 1876 | 185.330 |
2 | 2426 | 185.270 |
1 | 2151 | 185.230 |
2 | 6338 | 185.220 |
Price($) | Vol. | No. |
---|---|---|
185.880 | 70 | 1 |
186.090 | 50 | 1 |
186.510 | 122 | 1 |
186.680 | 1510 | 1 |
186.820 | 100 | 1 |
Last trade - 16.11pm 27/06/2025 (20 minute delay) ? |
Featured News
CBA (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online